EMA Refused: Raylumis (tanezumab) — Pfizer Europe MA EEIG

View source ↗

Summary

The EMA refused the marketing authorization for Raylumis (tanezumab) from Pfizer Europe MA EEIG for osteoarthritis and pain, with a decision dated 16 September …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis
• Pain

Drugs mentioned

• Raylumis (tanezumab)

Snippet

Status: Refused. Therapeutic area: Osteoarthritis;Pain. MAH: Pfizer Europe MA EEIG. Decision date: 16/09/2021